Bright Minds Biosciences (DRUG) Corporate Presentation summary

Targeted drug development for CNS and neuropsychiatric disorders

• Focus on novel chemical entities targeting serotonin (5-HT) signaling, specifically 5-HT2A and 5-HT2C receptors, for conditions like depression, epilepsy, and Prader-Willi Syndrome.

• Proprietary chemistry platform enables highly selective agonists with minimized cardiac toxicity risk by avoiding 5-HT2B activation.

Epilepsy program and BMB-101

• BMB-101 is a highly selective, G protein-biased 5-HT2C agonist with validated safety and pharmacokinetics in Phase 1.

• Demonstrates robust efficacy in developmental and epileptic encephalopathies (DEE), with sustained effect and reduced tolerance due to avoidance of beta-arrestin pathway.

• Phase 2 studies target absence seizures and DEE, using seizure diaries and EEG as primary endpoints.

• Addressable market includes a broad spectrum of epilepsies, with significant unmet need in drug-resistant cases.

• Favorable safety profile observed in clinical trials, with most adverse events being transient and dose-related.

Market opportunity and competitive positioning

• Estimated refractory epilepsy market opportunity is ~$21B, with absence epilepsy alone at ~$5.1B.

• BMB-101 is positioned as best-in-class due to its unique mechanism, safety, and flexible dosing.

• Company valuation is significantly lower than peers with marketed or late-stage rare epilepsy drugs.